Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.
Laura Goff, MD, associate professor of medicine (hematology/oncology), medical director, Division of Hematology and Oncology, co-chair, Data and Safety Monitoring Committee, Vanderbilt-Ingram Cancer Center, discusses the need to identify novel targets in hepatocellular carcinoma (HCC).
Data that was presented during the 2020 ASCO Virtual Scientific Program demonstrated modest activity with the VEGF inhibitors apatinib and donafenib in patients with HCC, says Goff.
However, these agents are similar to the already established VEGF inhibitors in the HCC paradigm, Goff explains.
As such, developing new agents that do not target VEGF or the immune system remains an area of need in HCC, Goff concludes.